Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update Presented Encouraging Phase 2 Data on NUC-7738 in Combination with Pembrolizumab at the European Society for...
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel Patients with Advanced Solid Tumors who had Exhausted All Other...
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States EDINBURGH, United Kingdom, Sept. 25, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced the...
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024 Combination of NUC-7738 plus...
NuCana Announces Update for Phase 2 Randomized Colorectal Cancer Study NuTide:323 Study to be Discontinued Following Pre-Planned Initial Analysis and Recommendation from the Steering Committee...
NuCana Reports Second Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024 Anticipated Cash Runway into Q1 2025 EDINBURGH, United...
NuCana to Present at the Jefferies Global Healthcare Conference NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive...
NuCana to Present at TD Cowen’s 5th Annual Oncology Innovation Summit EDINBURGH, United Kingdom, May 21, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh...
NuCana Reports First Quarter 2024 Financial Results and Provides Business Update Key Data Readouts on Track for All Programs in 2024 Randomized Phase 2 Study of 182 Second-Line Colorectal...
NuCana Regains Compliance with Nasdaq Minimum Bid Price Requirement EDINBURGH, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA), (“NuCana” or the “Company”...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0.36 | 1.3 | 0.174 | 12483 | 0.32118086 | DE |
| 156 | 0 | 0 | 0.5749999 | 1.3 | 0.174 | 11092 | 0.33522586 | DE |
| 260 | 0 | 0 | 0.5749999 | 1.3 | 0.174 | 11092 | 0.33522586 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
